Fig. 6

Abrogating the 4-1BB interaction with A20 improves the antitumor effects of CAR-T cells. A Representative flow cytometry plots of the experiments in which CAR-T cells were cocultured with Daudi cells for five days (E:T ratio of 1:5). At day five cells were collected to measure Daudi cells (CD20⁺) and T cells (CD3⁺) by flow cytometry. NT indicates control non-transduced T cells. B, C Summary of the coculture experiments illustrated in (A); n = 6, *p < 0.05, one-way ANOVA. D Heatmap of DEGs comparing 19.BBζ and BBζ ΔC10 CAR-T cells 24 h after activation with the anti-idiotype CAR.CD19 Ab; n = 3 for 19.BBζ and n = 2 for BBζ ΔC10. E KEGG pathway enrichment of DEGs comparing 19.BBζ and BBζ ΔC10 CAR-T cells illustrated in (D). F Schematic of the Daudi cell model in NSG mice to evaluate the antitumor effects of CAR-T cells in vivo. The i.v. indicates tail vein injection. G Kaplan–Meier survival curve of the Daudi tumor model illustrated in (F); n = 10, ***p < 0.001 by Log-rank test. H Numbers of CD3⁺CD45⁺ human T cells detected in the peripheral blood of mice of the Daudi tumor model collected on day 21 post-T-cell infusion; n = 5, *p < 0.05, one-way ANOVA. I, J Numbers of CD3⁺CD45⁺ human T cells in the peripheral blood (G) and spleen (H) of the mice of the Daudi tumor model at the time of euthanasia from day 25 to day 60 after CAR-T cell infusion; n = 5, *p < 0.05, one-way ANOVA